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In the present study we aimed to verify if the enhancement of glial cell line-derived neurotrophic factor
(GDNF) production in mouse striatum following treatment with LY379268 may also induce in the
nigrostriatal system a time-related activation of RET receptor and its speciﬁc intracellular signaling. For
this purpose, we have investigated the effects of LY379268 treatment on RET phosphorylation at the
Tyr1062 and on downstream signaling Erk1/2, Akt and PLCg1 pathway activation. The results showed
that treatment with LY379268 (3 mg/kg) induces a signiﬁcant increase of GDNF levels and time-related
RET and Erk1/2 phosphorylation in the striatum. These increases were detected at 24 h and 48 h
following LY379268 treatment. No changes were observed in the Akt and PLCg1 phosphorylation levels.
Similar results for p-Erk1/2 were observed in the substantia nigra. A complete block of LY379268 effect
on striatal RET and p-Erk1/2 phosphorylation was observed in mice intrastriatal injected with anti-GDNF
antibodies, suggesting a correlation between GDNF upregulation and RET activation. Overall, with
present data we have shown that activation of mGluR2/3 receptors by LY379268 may be particularly
promising for nigrostriatal dopaminergic system protection by enhancing striatal levels of GDNF/RET
trophic system activity.
 2011 Elsevier Ltd. All rights reserved.
1. Introduction
Glial cell line-derived neurotrophic factor (GDNF) and its
receptors constitute a physiological trophic system in the basal
ganglia with critical trophic role for the maturation of dopami-
nergic neurons, for cell survival and ﬁbre innervations (Li et al.,
2006). Following the discovery of GDNF, several studies demon-
strated that GDNF protein, infused into the nigral region, is efﬁca-
cious in reducing or preventing dopaminergic toxicity in rodent
models of Parkinson’s disease (Beck et al., 1995; Kearns et al., 1997;
Tomac et al., 1995a; Soderstrom et al., 2006). In primate model of
Parkinson’s disease, GDNF protects dopaminergic neurons in the
substantia nigra, maintains dopamine levels in striatum, and
improves Parkinsonian symptoms (Gash et al., 1996; Costa et al.,
2001; Slevin et al., 2005). Several clinical trials using GDNF
protein intrastriatal infusion were also conducted in Parkinson’s
disease patients (Kordower et al., 1999; Nutt et al., 2003; Gill et al.,
2003; Patel et al., 2005; Slevin et al., 2005), but many of these trials
reported several side effects and no improvements of disease. The
delivery of GDNF to the central nervous system is challenging
because GDNF is unable to cross the bloodebrain barrier (Kirik
et al., 2004), and several problems also come with GDNF expres-
sion induced by viral vectors, or with the use of encapsulated GDNF
producing cells (Bespalov and Saarma, 2007). However, since
currently GDNF raises great expectations as a potential therapeutic
agent for the treatment of Parkinson’s disease and other neurode-
generative diseases, the development of drugs that administered
systemicallymay enhance endogenous GDNF expression or activate
the GDNF receptor, is an attractive idea as therapeutic option for
Parkinson’s disease. In this context, recently we reported that
treatment with (1R,4R,5S,6R)-4-Amino-2-oxabicyclo[3.1.0]hexane-
4,6-dic arboxylic acid (LY379268), a selective mGlu2/3 receptor
agonist, induces a signiﬁcant enhancement of striatal GDNF and
attenuates the loss of dopaminergic neurons from the substantia
nigra in the MPTP mouse model (Battaglia et al., 2009).
In the adult nigrostriatal system endogenous GDNF acts as
a target-derived factor for dopaminergic neurons (Tomac et al.,
Abbreviations: GDNF, glial cell line-derived neurotrophic factor; LY379268,
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1995b; Oo et al., 2005) and produces neurotrophic and neuro-
protective effects through RET receptor tyrosine kinase and four
different glycosylphosphatidylinositol (GPI)-linked receptors
(GFRa1e4). Homodimeric GDNF binds ﬁrst to monomeric or
dimeric GFRa1 and the complex brings two RET molecules
together, and tyrosine residues in the intracellular domains of the
RET proteins are autophosphorylated (Bespalov and Saarma, 2007;
Trupp et al., 1996). Tyrosine autophosphorylation is required for the
catalytic activity of RET and for downstream signaling and consti-
tutes the ﬁrst intracellular event of the RET signaling cascade
activated by members of the GDNF ligand family. RET short and
middle isoforms contain 16 tyrosine residues in their intracellular
domains and RET long isoform has two additional tyrosines in the
carboxy-terminal tail. Like other receptor tyrosine kinases, RET can
activate different signaling pathways including Ras/Erk, PI3K/Akt,
p38/MAPK, PLCg and c-Jun N-terminal kinase (JNK) (Worby et al.,
1996; Xing et al., 1998; Chiariello et al., 1998; Trupp et al., 1999;
Soler et al., 1999; Hayashi et al., 2000; Takahashi, 2001; Sariola
and Saarma, 2003). Among the various tyrosine kinase of RET, it
has been demonstrated that Tyr1062 is involved in the activation of
Ras/Erk or PI3K/Akt pathways (Besset et al., 2000; Hayashi et al.,
2000, 2001; Murakami et al., 1999a, 1999b) and it is required for
GDNF-mediated differentiation and survival of neurons (Coulpier
et al., 2002; Califano et al., 2000; De Vita et al., 2000; Asai et al.,
1996; Besset et al., 2000)
As extension of previous work (Battaglia et al., 2009), in the
present study we aimed to verify if the enhancement of GDNF
production in mouse striatum following treatment with LY379268
may also induce in the nigrostriatal system a time-related activa-
tion of RET receptor and its speciﬁc intracellular signaling. For this
purpose, we have investigated the effects of LY379268 treatment on
RET phosphorylation at the Tyr1062, by using antibodies recog-
nizing the speciﬁc phosphorylation of Tyr1062 in the RET receptor,
and on downstream signaling Erk1/2 and Akt pathway activation.
We focus our attention to RET Tyr1062 since, as abovementioned, it
has been involved in GDNF-mediated neuroprotection and
neuronal survival and axonal growth (Coulpier et al., 2002) by
activation of Ras/Erk or PI3K/Akt pathways.
2. Material and methods
2.1. Animals
Adult male C57BL6 mice (22e24 g b.w.) from local stock have been used for the
present study. The mice were kept under environmentally controlled conditions,
ambient temperature 24 C, humidity 40% and 12 h light/dark cycle with food and
water ad libitum. Procedures involving animals and their care were conducted in
conformity with the institutional guidelines that are in compliance with national
(D.L. n. 116,G.U., suppl. 40,18 Febbraio 1992) and international laws and policies (EEC
Council Directive 86/609, OJ L 358,1, Dec. 12, 1987; NIH Guide for the Care and Use of
Laboratory Animals, NIH Publication no. 80-23, 1985 and Guidelines for the Use of
Animals in Biomedical Research, Thromb. Haemost. 58, 107 8e1084, 1987).
2.2. Treatments
Mice were treated with mGluR2/3 selective agonist LY379268 (Tocris Biosci-
ence, Cat. N. 2453), dissolved in saline and administered systemically with a single
intraperitoneal (i.p.) injection of 3 mg/kg. Control mice received the same amount
of saline. Mice were sacriﬁced at scheduled time of 24 h, 48 h and 72 h from
treatment. We also used neutralizing goat anti-GDNF antibodies (R&D Systems
Cat.n. AF-212-NA) unilaterally injected into the right striatum. For striatal injection
of anti-GDNF antibodies the mice, under anesthesia, were placed in a David Kopf
(Tujunga, CA, USA) stereotaxic apparatus and injected using the following stereo-
taxic coordinates: A5.6, 4.6 and 3.6 mm, L1, 8 and V3 mm (Lehmann, 1974). The
injection of antibodies was made in three different antero-posterior positions in
order to spread the antibodies in a large area of striatum. The dose of neutralizing
anti-GDNF antibodies injected in the striatum was 0.5 mg in 0.5 ml of saline and the
following four groups of mice were used: group injected with saline and saline
treated; group injected with saline and treated with LY379268 (3 mg/kg i.p.); group
injected with neutralizing anti-GDNF antibodies (AF-212-NA, R&D Systems) and
treated with LY379268; group injected with neutralizing anti-GDNF antibodies and
saline treated. Following 2 h of striatal anti-GDNF antibodies injection, all mice
groups received saline or LY379268 and were sacriﬁced 24 h after the treatment.
Mice were killed under deep anaesthesia with chloral hydrate and brains were
rapidly removed and striatum and substantia nigra dissected out and immediately
frozen on dry ice and stored at 80 C. For each experimental condition three
independent experiments have been made and each experimental group consisted
of at least four mice.
2.3. GDNF, p-ret, p-Erk1/2, p-akt and p-PLCg1 analysis
Dissected tissues, striatum and substantia nigra, were homogenized at 4 C in
a buffer composed of TriseHCl 50 mM pH 7.4, NaF 50 mM, EDTA 2 mM, protease
inhibitor cocktail (P8340, SigmaeAldrich S.r.l., Milan, Italy) and phosphatase
inhibitor cocktail (P5726, SigmaeAldrich S.r.l., Milan, Italy). Half of the homogenate
was added with Triton X-100 1% and SDS 0.1%, left on ice for 30 min and then
centrifuged at 13,000 rpm for 30 min at 4 C; The supernatant was stored at 20 C,
aliquots were taken for protein determination by the method of Lowry et al. 1951
{LOWRY, 1951 589/id} and 50 mg of proteins were used for GDNF, p-Erk1/2, p-Akt
and p-PLCg1 western blots. The remaining half of the homogenate was left on ice for
30 min and then centrifuged at 13,000 rpm for 30 min at 4 C; the supernatant,
containing cytoplasmatic proteins, was discarded and the pellet instead was
homogenized in a buffer composed of TriseHCl 12.5 mM pH 7.4, SDS 0.5%, EDTA
2 mM, 1 mM DTT protease inhibitor cocktail (P8340, SigmaeAldrich S.r.l., Milan,
Italy) and phospatase inhibitor cocktail (P5726, SigmaeAldrich S.r.l., Milan, Italy);
the homogenate was left at room temperature for 30 min and then centrifuged at
13,000 rpm for 30 min at 4 C. The supernatant containing membrane proteins was
stored at 20 C, aliquots were taken for protein determination by the method of
Lowry et al. 1951 {LOWRY, 1951 589/id} and 50 mg of proteins were used for western
blotting. The samples and mol. wt. markers (161-0375, Bio-Rad Laboratories S.r.l.,
Segrate (MI), Italy), were run on 10% polyacrylamide gel for GDNF and p-Erk1/2, on
8% polyacrylamide gel for p-Akt and on 6% polyacrylamide gel for p-PLCg1 and p-Ret
at 100 V and electrophoretically transferred onto nitrocellulose membrane
(Hybond-C-extra, GE Healthcare, formerly Amersham, Europe GmbH e Filiale Ital-
iana, Milan, Italy). Themembraneswere incubated for 1 h in blocking buffer: 1 TBS,
0.1% Tween-20, 5% w/v nonfat dry milk. Following three washing for 5 min. with
TBS/T, the membranes were incubated with gentle shaking overnight at 4 C with
speciﬁc antibody in primary antibody dilution buffer: 1x TBS, 0.1% Tween-20, 5%
BSA. The following antibodies were used: anti-GDNF antibody (AF-212-NA, R&D
Systems 1:1000) or anti-phosphorylated Erk1/2 antibody (Rabbit phospho-p44/42
MAPK, Thr202/Tyr204 antibody 1:2000; 9101 Cell Signaling), or anti-
phosphorylated Akt (rabbit phospho-Akt (Ser473) antibody, 1:1000; 9271 Cell
Signaling) or anti-phosphorylated PLCg1 (rabbit phospho-PLCg1 (Tyr783) antibody,
1:1000; 2821 Cell Signaling), or anti-phoshorylated RET using antibody that selec-
tively recognizes phosphorylated RET in Tyr1062 (rabbit p-RET (Tyr1062) antibody
1:1000; sc-20252, Santa Cruz Biotechnology). Following three washing for 5 min
with TBS/T, the membranes were incubated for 1 h at room temperature with anti-
rabbit IgG horseradish peroxidase-conjugated diluted 1:5000 (Sc, 2004, Santa Cruz
Biotechnology) and relative bands were visualized with chemiluminescence reagent
(ECL, GE Healthcare, formerly Amersham, Europe GmbH e Filiale Italiana, Milan,
Italy) according to the manufacturer’s instructions. The blot is exposed to autora-
diography ﬁlm (Amersham Hyperﬁlm ECL; 28-9068-36), developed in Kodak D19
developer and ﬁxer (Eastman-Kodak, Rochester, NY, USA), and the densitometric
evaluation of bands was performed by measuring the optical density using NIH
ImageJ software. For the normalization of quantitative evaluation of bands each
membranewas stripped as follow:membranes were incubated at 37 C for 30min in
buffer containing Glicina 200mM, SDS 3mM,1% of Tween-20, pH 2.2. Following two
washing the membranes were reprobed for detection of respective protein by using
Rabbit anti-Erk1/2 antibody (9102, Cell Signaling 1:2000), or Rabbit anti-Akt anti-
body (9272, Cell Signaling 1:1000), or Rabbit anti- PLCg1 antibody (2822, Cell
Signaling 1:1000) or Rabbit anti-RET antibody (sc-13104, Santa Cruz Biotechnology
1:500). Mouse anti-bactin antibody (sc-47778, Santa Cruz Biotechnolog 1:6000) was
used for normalization of GDNF levels and for quantiﬁcation of total proteins of RET
and Erk1/2.
2.4. Statistical analysis
The bands on chemiluminescence-sensitive ﬁlm (Hyperﬁlm ECL, GE Health-
care, formerly Amersham) from each experiment were scanned using a not self-
calibrating ﬂatbed scanner (Epson Expression 1680 Pro) at a resolution of 1200
dots per inch (dpi). The optical density was assessed using the ImageJ software
(Rasband, W.S., ImageJ, U.S. National Institutes of Health, Bethesda, Maryland, USA,
http://rsb.info.nih.gov/ij/, 1997e2010), and the results analyzed by Prism 5 soft-
ware (Graph-Pad, San Diego, CA). The data were then evaluated by one-way
ANOVA with intergroup differences analysed by Fisher’s Protected Last Signiﬁ-
cant Difference PLSD test, or by t-test analysis. Data, representative of three or four
independent experiments with four-ﬁve mice for each experimental group, are
presented as arbitrary units, or as uncalibrated optical density, and are expressed as
mean  SEM.
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Fig. 1. Western blot analysis of GDNF and p-RET levels in the mouse striatum following LY379268 treatment (3 mg/kg). Data are representative of four independent experiments.
(AeB) GDNF 24 h and 48 h, and (CeE) p-RET levels at 24 h, 48 h and 72 h from LY379268 treatment. (F) Early time-points of LY379268 treatment effect on p-RET levels. (G) RET
protein levels. Histograms express the ratio of band intensity with respect to the loading control. bactin was used for normalization of GDNF and RET proteins levels. Data are
means  SEM of optical density (OD) values obtained from ﬁlms and expressed as arbitrary units. *P < 0.05, ***P < 0.001.
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Fig. 2. Western blot analysis of p-Erk1/2, p-Akt and p-PLCg1 levels in the mouse striatum and substantia nigra following LY379268 treatment (3 mg/kg). Data are representative of
four independent experiments. (AeB) striatal p-Erk1/2 levels at 24 h and 48 h from LY379268 treatment; (C) p-Akt and (D) p-PLCg1 levels in the striatum at 24 h from LY379268
treatment. (EeG) Substantia Nigra p-Erk1/2p-Akt and p-PLCg1 levels at 24 h from LY379268 treatment. (H) Erk1/2 protein levels. Histograms express the ratio of band intensity with
respect to the loading control. bactin was used for normalization of Erk1/2 protein levels. Data are means  SEM of optical density (OD) values obtained from ﬁlms and expressed as
arbitrary units. *P < 0.05, **P < 0.01, ***P < 0.001.
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3. Results
3.1. Striatal GDNF upregulation following LY379268 treatment
We ﬁrst veriﬁed the striatal response of GDNF levels to
LY379268 treatment using the best conditions revealed in our
previous work (Battaglia et al., 2009). Speciﬁcally, mice treated
with LY379268 (3 mg/kg b.w.) showed an signiﬁcant increase of
striatal GDNF levels both 24 h and 48 h following the treatment, as
compared to saline control (Fig. 1AeB).
3.2. RET receptor activation by LY379268 was time-related
to GDNF upregulation
Upon GDNF stimulation, the RET tyrosine kinase receptor is
autophosphorylated at a set of cytoplasmic tyrosine residues,
among which Tyr1062 in the carboxyl-terminal tail has been found
to be critical for GDNF signaling and for the binding of different
adaptor molecules (Airaksinen and Saarma, 2002). Here we
examined the effects of LY379268 treatment on activation levels of
RET Tyr1062 in both substantia nigra and striatum, since RET
protein has been found in the mesencephalic dopaminergic
neurons and their striatal terminals (Tsuzuki et al., 1995; Glazner
et al., 1998; Walker et al., 1998; Honda et al., 1999).
Concerning the striatal analysis, the results showed that treat-
ment with LY379268 (3mg/kg) induces a signiﬁcant increase of RET
phosphorylation on Tyr1062 as compared to control saline treated
(Fig. 1). This increase of Tyr1062 activationwas detected at 24 h and
48 h following LY379268 treatment (Fig. 1C and D) and therefore
was time-related to GDNF upregulation in the striatum. The RET
phosphorylation levels returned to basal condition at 72 h from
LY379268 treatment (Fig. 1E). No changes were observed in the
level of RET protein (Fig. 1G). The time-course of RET activation by
LY379268 treatment was extended also to earlier time-points, e.g.,
30 min., 1 h, and 2 h, in order to examine the potential activation of
RET dependent on acute GDNF release or on its transactivation
mediated by mGluR2/3 stimulation. However, the results showed
no changes in the RET phosphorylation levels at any time-point
examined (Fig. 1F).
The analysis of RET phosphorylation levels in the substantia
nigra showed unexpectedly a very low basal RET protein level and
the phosphorylated RET on Tyr1062 was undetectable in control
mice and apparently not increased following LY379268 treatment
(data not shown).
3.3. RET signaling pathway activation following LY379268
As above mentioned, RET receptor tyrosine kinase autophos-
phorylation can activate various signaling pathways including
RAS/Erk1/2, PI3K/Akt, PLCg, p38 MAPK and JNK pathways
(Takahashi, 2001). Particularly, it has been demonstrated that RET
phosphorylation at Tyr1062 is indispensable for the activation of
the Ras/Erk or PI3K/Akt pathways (Besset et al., 2000) and is
required for GDNF-mediated neuroprotection and survival of
neurons (Coulpier et al., 2002). Since we found a signiﬁcant
increase of phosphorylated RET on Tyr1062 following LY379268
treatment, we therefore decided to examine the effects of
LY379268 treatment on levels of p-Erk1/2 and p-Akt. Additionally
we veriﬁed the levels of the p-PLCg1 as Tyr1062 independent
pathway, and mainly involved in neuronal differentiation.
Phosphorylation levels of p-Erk1/2, p-Akt and p-PLCg1 were
investigated both in the striatum and substantia nigrawith focus on
the best time-point related to upregulation of RET Tyr1062 phos-
phorylation. The results showed that in the striatum p-Erk1/2 was
signiﬁcantly increased 24 h and 48 h after LY379268 treatment
(Fig. 2A and B). There was no signiﬁcant change in the level of non-
phosphorylated forms of ERK demonstrating that the speciﬁc
activation of ERK is through post-translational modiﬁcation by
phosphorylation rather than regulation of protein expression. By
contrast no changes were observed in the Akt (Fig. 2C) and PLCg1
(Fig. 2D) phosphorylation levels in the striatum.
The analysis of p-Erk1/2 levels in the substantia nigra showed,
like in the striatum, a signiﬁcant increase at 24 h from LY379268
treatment (Fig. 2E). By contrast no changes were observed in the
Akt (Fig. 2F) and PLCg1 phosphorylation levels (Fig. 2G).The upre-
gulation of p-Erk1/2 levels was not dependent on change in the
Erk1/2 protein levels (Fig. 2H).
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Fig. 3. Western blot analysis of p-RET and p-Erk1/2 levels in mice control or LY379268
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before of LY379268 (3 mg/kg) or saline treatment. Data are representative of three
independent experiments. (A and B) striatal p-RET and p-Erk1/2 levels at 24 h from
treatment. Histograms express the ratio of band intensity with respect to the loading
control. Data are means  SEM of optical density (OD) values obtained from ﬁlms and
expressed as arbitrary units. **P < 0.01, ***P < 0.001.
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3.4. Correlation between GDNF upregulation and RET activation
in the striatum
To examine the causal relationship between the increase in
GDNF levels and RET activation, we adopted a similar experimental
approach previously developed by Battaglia et al. 2009. We used
neutralizing anti-GDNF antibodies unilaterally injected into the
right caudate nucleus in order to verify if block of GDNF may
abrogate the RET activation and its intracellular signaling. The anti-
GDNF antibodies injection was made in three different antero-
posterior positions in order to spread the antibodies in a large
area of striatum. The dose of neutralizing anti-GDNF antibodies was
0.5 mg/0.5 ml of saline for each injection and the following groups of
mice were used: group injected with saline and saline treated;
group injected with saline and treated with LY379268 (3 mg/kg
i.p.); group injected with neutralizing anti-GDNF antibodies and
treated with LY379268; group injected with neutralizing anti-
GDNF antibodies and treated with saline. All mice 2 h after stria-
tal injection received the saline or LY379268 treatment and were
sacriﬁced after 24 h. The results obtained (Fig. 3A) showed
a signiﬁcant block of LY379268-induced RET phosphorylation in
the striatum of mice treated with anti-GDNF antibodies, suggesting
a correlation between GDNF upregulation by LY379268 treatment
and RET activation.
In the same condition, the striatal p-Erk1/2 increase observed
following LY379268 treatment was also blocked in mice injected
with anti-GDNF antibodies (Fig. 3B), suggesting a functional
correlation between RET activation and downstream signaling
involving Erk1/2 pathway.
4. Discussion
As underlined in the introduction, this work was undertaken in
order to extend our previous ﬁndings showing the ability of
LY379268 to enhance the GDNF levels in the striatum and conse-
quently to be neuroprotective in mouse model of Parkinson’s
Disease (Battaglia et al., 2009). In the present study we could reveal
that the enhancement of GDNF levels in mouse striatum by
LY379268 treatment is followed by phosphorylation of RET
receptor on Tyr1062 and that Erk1/2 is the intracellular signaling
pathway linked to RET activation. In fact, the striatal p-Erk1/2
increase observed following LY379268 treatment was also blocked
in mice injected with anti-GDNF antibodies (Fig. 3B), suggesting
a functional correlation between RET activation and downstream
signaling involving Erk1/2 pathway. Based on this upregulation of
p-ERK1/2, although it needs to be further veriﬁed, we can speculate
that the MAP/ERK pathwaymay be responsible for GDNF-mediated
nigrostriatal neuroprotection observed in the MPTP mouse model
of Parkinson’s disease (Battaglia et al., 2009).
In the adult striatum, endogenous GDNF expression has been
detected only at very low levels and in scattered cells throughout
the caudate nucleus, putamen, and internal and external segments
of the globus pallidus (Battaglia et al., 2009). The diverse biological
actions of GDNF are mediated through its RET receptor tyrosine
kinase (Trupp et al., 1996; Yu et al., 1998; Paratcha et al., 2001) and
RET protein has been found expressed in the mesencephalic
dopaminergic neurons and their striatal terminals, but not in the
intrastriatal neurons (Trupp et al., 1997; Golden et al., 1998; Tsuzuki
et al., 1995; Glazner et al., 1998; Walker et al., 1998; Honda et al.,
1999; He et al., 2008). However, in our hand, it was possible to
detect RET protein in the striatum but not in the substantia nigra.
These observations suggested that GDNF is functioning as a target-
derived factor to maintain dopaminergic neuronal circuits within
the basal ganglia (Barroso-Chinea et al., 2005; Tomac et al., 1995b).
GDNF binding to RET receptor lead to tyrosine kinase
autophosphorylation at a set of 16 cytoplasmic tyrosine residues, in
the RET short and middle isoforms, and two additional tyrosines in
the carboxy-terminal tail, in the RET long isoform. RET receptor
tyrosine kinase autophosphorylation can activate various signaling
pathways including RAS/ERK, PI3K/AKT and p38MAPK (Worby
et al., 1996; Xing et al., 1998; Chiariello et al., 1998; Trupp et al.,
1999; Soler et al., 1999; Hayashi et al., 2000; Takahashi, 2001;
Sariola and Saarma, 2003). Particularly, it has been demonstrated
that Tyr1062 is involved in the activation of Ras/Erk or PI3K/Akt
pathways (Besset et al., 2000; Hayashi et al., 2000, 2001; Murakami
et al., 1999a, 1999b) and is required for GDNF-mediated neurons
differentiation and survival (Coulpier et al., 2002; Califano et al.,
2000; De Vita et al., 2000).
In the present work, the RET phosphorylation on Tyr1062 was
found linked with increased activity of Erk1/2 pathway both in the
striatum and substantia nigra. By contrast, no changes were
observed in the Akt and PLCg1 phosphorylation in both brain
regions.
Following neurotrophin stimulation of distal axons, multiple
signaling pathways are activated locally within the axons. These
include retrograde neurotrophic signaling, which plays a critical
role in regulating neuronal growth, survival and differentiation of
innervating neurons, and signaling molecules, such as PI3K/Akt,
MAPK/Erk1/2 and Erk5 which promote local effects such as axonal
outgrowth and synaptic plasticity (Ginty and Segal, 2002).
Increasing evidence suggest that endosomes containing neuro-
trophin/receptor activated complexes and other signaling proteins
of the Ras/Erk1/2, p38MAPK, and PI3K/Akt pathways serve as an
important source of neurotrophic retrograde signals (Wu et al.,
2009; Ginty and Segal, 2002; Coulpier and Ibanez, 2004). Using
an in vitro model, GDNF stimulation of distal axons resulted in
activation of downstream signaling of Erk1/2 and Akt phosphory-
lation in the axons, and RET and Akt phosphorylation in the cell
bodies, demonstrating the retrograde propagation of an intracel-
lular GDNF-mediated signal (Coulpier and Ibanez, 2004; Tomac
et al., 1995b). A retrograde propagation of GDNF signaling is also
supported by data showing Erk1/2 activation in the substantia nigra
following striatal GDNF injection (Salvatore et al., 2004; Lindgren
et al., 2008). In the present study, following LY379268 treatment
Erk1/2 signaling pathway was found signiﬁcantly activated also in
the substantia nigra.
Although the increased levels of phosphorylated RET were
found time-related to GDNF protein upregulation, in order to verify
the direct link between LY379268-induced GDNF and the RET
activation we adopted the strategy based on the injection of
neutralizing anti-GDNF antibodies in the striatum. The injection of
anti-GDNF antibodies in the striatumwas signiﬁcantly able to block
the effects of LY379268 on RET and Erk1/2 activation in the stria-
tum, suggesting a GDNF-dependent RET phosphorylation following
LY379268 treatment. This approach was also successful in
a previous paper, where we could show that LY379268 treatment
loses its neuroprotective activity after anti-GDNF antibodies
implantation in the striatum (Battaglia et al., 2009). However,
following LY379268 treatment we could not observe a complete
block of RET phosphorylation probably because the neutralizing
anti-GDNF antibodies injection in three striatal position was not
enough to cover all the striatum.
The activation of mGluR2/3 have been implicated in the
production of other neurotrophic factors, such as TGFb1 in astro-
cytes (Bruno et al., 1998; Ciccarelli et al., 1997) and in the striatum
(D’Onofrio et al., 2001), or BDNF in microglia (Matarredona et al.,
2001; Venero et al., 2002), in the hippocampus (Di Liberto et al.,
2010), in neuronal hippocampal cultures (Canossa et al., 2001;
Wu et al., 2004; Marini et al., 1998) and in reactive astrocytes
(Mudo et al., 2007; Ohishi et al., 1993, 1998). Although this proved
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involvement of mGluR2/3 in neurotrophic factors regulation, the
present data, together with previous related ﬁndings (Battaglia
et al., 2009), provide a complete demonstration for an involve-
ment of GDNF/RET neurotrophic system in the neuroprotection
observed in the mouse model of Parkinson’s disease following
mGluR2/3 activation.
GDNF and its receptor constitute a physiological trophic system
in the basal ganglia with critical trophic role for the maturation of
dopaminergic neurons, for cell survival and ﬁbre innervations
(Li et al., 2006). GDNF has been evaluated in several clinical trials
for its effect on Parkinson’s disease (Kordower et al., 1999; Gill et al.,
2003; Slevin et al., 2005; Lang et al., 2006), according with its
consistent neuroprotective and restoring activity in experimental
models of parkinsonism. The major limitation associated with the
peripheral administration of GDNF as therapy for neurodegenera-
tive disorders and brain injury is the poor penetration across the
bloodebrain barrier. Therefore, the use of low-molecular weight
drugs, such as LY379268, that administered systemically may
enhance endogenous GDNF/RET neurotrophic system is relevant in
order to overcome most of the problems associated with the
delivery of GDNF protein into the brain. Therefore, with the present
results we contributed to reveal the possibility that pharmacolog-
ical activation of mGluR2/3 may slow the progression of neurode-
generative disorders through the mechanism based on the
production of endogenous GDNF/RET neurotrophic system.
5. Conclusions
Overall, with previous (Battaglia et al., 2009) and present data we
have shown that activation of mGluR2/3 receptors by LY379268 is
particularly promising for the experimental treatment of Parkinson’s
disease, since it may protect nigrostriatal dopaminergic system by
enhancing striatal levels of GDNF/RET trophic system activity.
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